From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

Sep 24, 2026

Uploaded by moss~

Cancerous inhibitor of protein phosphatase 2A (CIP2A), also known as p90, is highly expressed across many solid and hematological tumors, where it can shape oncogenic biology by modulating PP2A activity toward c-Myc. The resulting signaling effects are linked to tumor cell proliferation, invasion, migration, and drug resistance. Because CIP2A/p90 signaling and regulatory networks remain incompletely understood, the review emphasizes recent mechanistic advances and evaluates CIP2A/p90 as a therapeutic target and as an autoantibody-based biomarker for diagnosis and prognosis.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages17

Reading Time43 min

AccessFree to download

Introduction

The function of CIP2A/p90 in cancers

TYPE Review PUBLISHED 24 February 2023 DOI 10.3389/fgene.2023.1110656 OPEN ACCESS EDITED BY Bin Fang, the First Afﬁliated Hospital of Guangzhou University of Chinese Medicine, China REVIEWED BY Jianxian Lin, Fujian Medical University Union Hospital, China Guifang Guo, Sun Yat-sen University Cancer Center (SYSUCC), China Chenchen Wang, Fudan University, China *CORRESPONDENCE Xiaobing Chen, [zlyychenxb0807@zzu.edu.cn](zlyychenxb0807@zzu.edu.cn) SPECIALTY SECTION This article was submitted to Cancer Genetics and Oncogenomics, a section of the journal Frontiers in Genetics RECEIVED 29 November 2022 ACCEPTED 03 February 2023 PUBLISHED 24 February 2023 CITATION Chen B, Hu H and Chen X (2023), From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer. Front. Genet. 14:1110656 . doi: 10.3389/fgene.2023.1110656 COPYRIGHT © 2023 Chen, Hu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer Beibei Chen 1,2, Huihui Hu 1,2 and Xiaobing Chen 1,2* 1Department of Medical Oncology, Afﬁliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China, 2Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, Henan, China Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can hinder the function of PP2A toward c-Myc S62 induction, thus stabilizing c-Myc protein, which represents a potential role of CIP2A/p90 in tumorigeneses such as cell proliferation, invasion, and migration, as well as cancer drug resistance. The signaling pathways and regulation networks of CIP2A/p90 are complex and not yet fully understood. Many previous studies have also demonstrated that CIP2A/p90 can be used as a potential therapeutic cancer target. In addition, the autoantibody against CIP2A/p90 in sera may be used as a promising biomarker in the diagnosis of certain types of cancer. In this Review, we focus on recent advances relating to CIP2A/p90 and their implications for future research. KEYWORDS CIP2A/p90, cancer, tumor-associated antigen (TAA), signaling pathways, biomarker, prognosis 1 Introduction The sera of patients diagnosed with cancer contain antibodies that can react with a unique group of autologous cellular proteins called tumor-associated antigens (TAAs) (Chenet al., 2018) . The immune system of cancer patients is a sensor of alterations in the structure and/or function of participants in tumorigenesis pathways and is capable of immune responses in the form of autoantibodies against these TAAs (Jhunjhunwala et al., 2021) . Circulating autoantibodies have been used as ’probes’ in cancer patients to isolate TAAs, which have been shown to be cellular factors participating in known tumorigenesis pathways (Tan, 2001; Tan and Zhang, 2008; Zhang et al., 2022) . The constitution of TAAs do not include all cellular antigens identiﬁed by autoantibodies in cancer sera as some autoantibodies may exist in conditions that pre-date malignancy. Thus, many approaches aimed at identifying and characterizing authentic TAAs have been identiﬁed by anti-TAA autoantibodies, which can be used as biomarkers for diagnosis or early detection only after extensive evaluation with canc

FAQs

What is CIP2A/p90 and why is it important in cancer?

CIP2A, initially reported as the tumor-associated antigen p90, is highly expressed in many cancers. Its interaction with PP2A and c-Myc can stabilize c-Myc and support tumor-related processes.

How does CIP2A/p90 influence PP2A and c-Myc signaling?

CIP2A/p90 can hinder PP2A’s function toward c-Myc S62 induction, which helps stabilize c-Myc protein. This mechanism is associated with proliferation, invasion, migration, and drug resistance.

How can CIP2A/p90 be used clinically as a biomarker or therapeutic target?

CIP2A/p90 can be explored as a potential therapeutic cancer target. Autoantibodies against CIP2A/p90 in sera are also described as promising biomarkers for diagnosis of certain cancer types and for prognosis.

Sep 24, 2026

Uploaded by moss~